



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, April 7th, 2022 1:00 - 5:00 PM

Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Cat Livingston, MD; Tim Langford, PharmD; Robin Moody, MPH; Bill Origer, MD; Russ Huffman, PMHNP; Patrick DeMartino, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Amanda Parish, LCSW; Sarah Servid, PharmD; Megan Herink, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Kathy Sentena, PharmD; Deborah Weston, JD

Audience: **Stuart O'Brochta*** - Gilead, **Charlie Lovan*** - Abbvie, **Amy Burns*** - Allcare, **Andy Seaman*** - OHSU, **Ann Thomas*** - OHA Center for Public Health Practice, Baltazar Chavez-Diaz – PacificSource Health Plan, Beth Englander – Oregon Law Center, Brandie Feger – Advanced Health, Casey Eastman, Claudette Banks - OHSU, Dennis Schaffner – Sanofi Specialty Care, **Douglas Carr*** – **CMO Umpqua Health Alliance**, Ed Eldridge, Emma Anderson – Sick Cells, Jason Kniffin, Jeff Mussack - Immunocore, Jeremy Strand - Alexion, Jim Slater - CareOregon, **Kate Jelline*** - **Ardon Health Specialty Pharmacy**, Katie Scheelar – EOCCO/Moda Health, Kelly Wright – Gilead, Kenneth Orr – Global Blood Therapeutics, Laura Jeffcoat - Abbvie, **Lorren Sandt*** – **Caring Ambassadors Program**, Mark Kantor – AllCare Health, Matt Worthy - OHSU, Melissa Bailey-Hall, Melissa Snider - Gilead, Michael Foster - BMS, Michele Sabados, Mike Donabedian – Sarepta Therapeutics, Mit Patel - Calliditas, Nana Ama Kuffour - IHN, Olaf Reinwald – Global Blood Therapeutics, **Robin Traver*** – **Umpqua Health Alliance**, Roy Lindfield - Sunovion, Saghi, **Santries Booze*** – **Global Blood Therapeutics**, Shannon Lee - Trillium, Shauna Wick - Trillium, Steve Angelcyk – BD Diabetes, Terence Lee - Gilead, Tiffany Jones – Pacific Source, Tina Andrews – Umpqua Health Alliance, Brandon Yip – Sanofi, YJ Shukla – EOCCO/Moda Health

(*) Provided verbal testimony

Written testimony: Posted to OSU Website

I.

CALL TO ORDER

- A. Roll Call & Introductions
 - Called to order at approx. 1:02 p.m., introductions by Committee and staff
- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Approval of Agenda and February 2022 Minutes presented by Roger Citron
ACTION: Motion to approve, 2nd, all in favor
- D. Department Update provided by Andrew Gibler, PharmD
- E. Legislative Update provided by Dee Weston, JD

II. **CONSENT AGENDA TOPICS**

- A. **Oncology Prior Authorization (PA) Updates**
Recommendation:
 - Add: Kimmtrak® (tebentafusp) to Table 1 in the Oncology Agents prior authorization (PA) criteria
- B. **Orphan Drug Policy Updates**
Recommendation:
 - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Enjaymo™ (sutimlimab-jome) based on FDA-approved labeling**ACTION: Motion to Approve, 2nd, all in favor**

III. **DUR NEW BUSINESS**

- A. **Citizenship Waived Medical (CWM) Coverage Update:** Sarah Servid, PharmD
Recommendation:

Implement PA criteria for drugs prescribed for patients with the CWM benefit, and update PA criteria with relevant diagnoses if emergency drug coverage is expanded to other conditions in the future

ACTION: Motion to approve, 2nd, all in favor with one abstention
- B. **Prior Authorization Updates:** Sarah Servid, PharmD
 - a. **Botulinum Toxins PA Update**
Recommendation:
 - Update PA criteria as proposed**ACTION: Motion to approve, 2nd, all in favor**
 - b. **Drugs for Non-Funded Conditions PA Update**
Recommendation:

- Update PA criteria as proposed to align with final version of Statement of Intent 4 (SOI4)

ACTION: Motion to approve, 2nd, all in favor

c. Non-Preferred Drugs in Select PDL classes PA Update

Recommendation:

- Update PA criteria as proposed to align with final version of Statement of Intent 4 (SOI4)

ACTION: Motion to approve, 2nd, all in favor

IV. DUR OLD BUSINESS

A. Hepatitis C Direct-Acting Antivirals Policy Discussion

Policy Discussion: Andrew Gibler, PharmD; Dee Weston, JD

Prior Authorization Update: Megan Herink, PharmD

Public Comment:

Charlie Lovan, AbbVie; Stuart O'Brochta, Gilead; Amy Burns, AllCare CCO; Robin Traver, Umpqua Health CCO; Douglas Carr, Umpqua Health CCO; Kate Jelline, Ardon Health Specialty Pharmacy; Lorren Sandt, Caring Ambassadors Program; Andy Seaman, Central City Concern; Ann Thomas, OHA Public Health

Recommendations:

-Remove PA criteria and required case management for preferred DAA regimens for treatment-naïve patients with hepatitis C virus

ACTION: Motion to Approve, 2nd, all in favor with one abstention

-Continue to require PA for: retreatment of HCV; non-preferred DAAs; and for uses not FDA approve

ACTION: Motion to Approve, 2nd, all in favor

- Make sofosbuvir/velpatasvir/voxilaprevir (Vosevi®) non-preferred and continue to reserve it for treatment-experienced individuals

ACTION: Motion to Approve, 2nd, all in favor

V. PREFERRED DRUG LIST NEW BUSINESS

A. Sickle Cell Disease Literature Scan: Kathy Sentena, PharmD

Recommendations:

- No Preferred Drug List (PDL) changes recommended based on the clinical evidence

- Update PA criteria to include the expanded age indication for voxelotor

- Evaluate costs in executive session

Public Comment: Santries Booze, Global Blood Therapeutics

ACTION: The Committee recommended: removing baseline pain crisis from approval criteria #8 for voxelotor approval; reword question #6 in approval criteria to change “failure” of hydroxyurea to “has the patient received (or have contraindications to) a 3 month trial of hydroxyurea at stable doses and will treatment of hydroxyurea be maintained”; reword question #7 in renewal criteria to simply require documented improvement from baseline (similar to question #5); and add “in pain symptoms” to #5 of renewal criteria

Motion to approve, 2nd, all in favor

B. Fabry Disease Literature Scan: Deanna Moretz, PharmD

Recommendation:

- Revise PA criteria to reflect expanded indication for agalsidase beta

ACTION: Motion to approve, 2nd, all in favor

C. Voxzogotm (vosoritide) New Drug Evaluation: David Engen, PharmD

Recommendation:

- Implement proposed PA criteria for vosoritide to ensure appropriate use

ACTION: Motion to approve, 2nd, all in favor

D. Vyvgarttm (efgartigimod alfa-fcab) New Drug Evaluation: Kathy Sentena, PharmD

Recommendations:

- Designate efgartigimod as non-preferred on the PDL and subject to PA criteria
- Implement proposed PA criteria to ensure appropriate use

ACTION: Motion to approve, 2nd, all in favor

E. Fluoroquinolone Drug Class Update: Deanna Moretz, PharmD

Recommendations:

- Designate moxifloxacin as a preferred on the PDL
- Review drug costs in Executive Session

ACTION: Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

Members Present: Cat Livingston, MD; Tim Langford, PharmD; Bill Origer, MD; Russ Huffman, PMHNP; Patrick DeMartino, MD; Eddie Saito, PharmD; Robin Moody, MPH

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Megan



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

Herink, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Kathy Sentena, PharmD; Deborah Weston, JD

VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Sickle Cell Disease Literature Scan

Recommendation: No PDL changes recommended

ACTION: Motion to approve, 2nd, all in favor

B. Fluoroquinolone Drug Class Update

Recommendations: No PDL changes recommended

ACTION: Motion to approve, 2nd, all in favor

VIII. ADJOURN